KPTI
Karyopharm Therapeutics Inc.
$9.10
-5.60%
$206.2M
No data for this timeframe.
Vol
Market Cap$206.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders40 funds
Inst. Value$51.5M
Inst. Activity8 buys / 1 sells
Insider Activity0B / 13S
Insider Net $-$294.7K
SEC Reports11
Recent Activity
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Selinexor (Phase 2)
Trial: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Pre
May 26, 2026
SEC
Six KPTI insiders, including the CEO and other C-suite executives, sold a total of $35K in shares on May 14, 2026, the s
CLUSTER — Impact 3/10
May 26, 2026
SEC
Six KPTI insiders, including CEO Richard Paulson, sold shares on May 14 (the same day as Q1 earnings), totaling $35,000
CLUSTER — Impact 2/10
May 21, 2026
Insider
Greene Barry E was granted 15,508 shares
Director
May 21, 2026
Insider
Su Zhen was granted 15,508 shares
Director
May 21, 2026
Insider
Schor Chen was granted 15,508 shares
Director
May 15, 2026
SEC
Six Karyopharm executives, including the CEO and C-suite, sold a total of $35K in open-market shares on May 14, 2026, on
CLUSTER — Impact 6/10
Inst.
RA CAPITAL MANAGEMENT, L.P. — NEW
1,917,354 shares ($10.7M)
Price Targets
$13.50
+48.4% upside
Strong Buy
Current $9.10
Low $7.00
Median $14.50
High $16.00
6 analysts
$7.00
$16.00
Analyst Ratings
4Strong Buy
7Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 27, 2026 | Piper Sandler | REITERATE | Overweight → Overweight |
| Mar 30, 2026 | Piper Sandler | REITERATE | Overweight → Overweight |
| Mar 25, 2026 | Baird | MAINTAIN | Outperform → Outperform |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.39 ▼ -22.7% | $-1.68 — $-1.11 | 66% YoY | 3 |
| Next Q | $-1.21 ▼ -8.0% | $-1.61 — $-0.81 | 68% YoY | 3 |
| Current FY | $-4.95 ▼ -3.7% | $-6.03 — $-3.58 | 59% YoY | 3 |
| Next FY | $-4.89 ▼ -12.0% | $-6.57 — $-3.21 | 1% YoY | 2 |
Latest Reports
NEUTRAL
CLUSTER
3/10
Six KPTI insiders, including the CEO and other C-suite executives, sold a total of $35K in shares on May 14, 2026, the s
May 26, 2026
NEUTRAL
CLUSTER
2/10
Six KPTI insiders, including CEO Richard Paulson, sold shares on May 14 (the same day as Q1 earnings), totaling $35,000
May 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $10.7M | NEW |
| ADAGE CAPITAL PARTNERS GP, | $10.1M | DOUBLED |
| GOLDMAN SACHS GROUP INC | $5.3M | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $4.8M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | Greene Barry | A | $0.00 |
| May 21, 2026 | Su Zhen | A | $0.00 |
| May 21, 2026 | Schor Chen | A | $0.00 |
| May 21, 2026 | Oliger Christy | A | $0.00 |
| May 14, 2026 | Mano Michael | SELL | $2.5K |
40 institutional holders with $51.5M total value (9,260,025 shares) as of 2026-Q1. Top holders: RA, ADAGE, GOLDMAN. Net buying activity: 8 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 1,917,354 | $10.7M | 20.7% | NEW |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,806,322 | $10.1M | 19.5% | DOUBLED +328.7% |
| 3 | GOLDMAN SACHS GROUP INC | 947,579 | $5.3M | 10.2% | — |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 865,000 | $4.8M | 9.4% | — |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 739,745 | $4.1M | 8.0% | — |
| 6 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 425,900 | $2.4M | 4.6% | — |
| 7 | CITADEL ADVISORS LLC | 258,200 | $1.4M | 2.8% | — |
| 8 | Trexquant Investment LP | 257,903 | $1.4M | 2.8% | DOUBLED +518.0% |
| 9 | CITADEL ADVISORS LLC | 249,300 | $1.4M | 2.7% | — |
| 10 | BlackRock, Inc. | 244,899 | $1.4M | 2.6% | — |
| 11 | Brevan Howard Capital Management LP | 212,367 | $1.2M | 2.3% | — |
| 12 | GROUP ONE TRADING LLC | 191,527 | $1.1M | 2.1% | ADD +87.0% |
| 13 | TWO SIGMA INVESTMENTS, LP | 151,232 | $842.4K | 1.6% | — |
| 14 | MARSHALL WACE, LLP | 128,451 | $715.5K | 1.4% | — |
| 15 | VANGUARD FIDUCIARY TRUST CO | 114,934 | $640.2K | 1.2% | — |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 105,414 | $587.2K | 1.1% | ADD +75.9% |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 100,000 | $557.0K | 1.1% | — |
| 18 | STATE STREET CORP | 80,742 | $449.7K | 0.9% | ADD +37.0% |
| 19 | Connor, Clark & Lunn Investment Management Ltd. | 79,081 | $440.5K | 0.9% | ADD +38.2% |
| 20 | BALYASNY ASSET MANAGEMENT L.P. | 70,748 | $394.1K | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 1,917,354 | — | $10.7M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 421,322 | 1,806,322 | +328.7% | $10.1M | 2026-Q1 |
| Trexquant Investment LP | DOUBLED | 41,733 | 257,903 | +518.0% | $1.4M | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 102,419 | 191,527 | +87.0% | $1.1M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 59,914 | 105,414 | +75.9% | $587.2K | 2026-Q1 |
| STATE STREET CORP | ADD | 58,942 | 80,742 | +37.0% | $449.7K | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 57,212 | 79,081 | +38.2% | $440.5K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 48,088 | 19,472 | -59.5% | $108.5K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 8,858 | 18,570 | +109.6% | $103.4K | 2026-Q1 |
| VANGUARD GROUP INC | ADD | 408,222 | 559,619 | +37.1% | $4.1M | 2025-Q4 |
| GROUP ONE TRADING LLC | ADD | 68,436 | 102,419 | +49.7% | $753.8K | 2025-Q4 |
| STATE STREET CORP | ADD | 46,342 | 58,942 | +27.2% | $433.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 94 | 48,088 | +51057.4% | $353.9K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 25,766 | 8,858 | -65.6% | $65.2K | 2025-Q4 |
| GROUP ONE TRADING LLC | TRIM | 97,900 | 68,436 | -30.1% | $447.6K | 2025-Q3 |
| UBS Group AG | TRIM | 161,900 | 59,685 | -63.1% | $390.3K | 2025-Q3 |
| STATE STREET CORP | ADD | 33,295 | 46,342 | +39.2% | $303.1K | 2025-Q3 |
| Baird Financial Group, Inc. | DOUBLED | 10,532 | 25,932 | +146.2% | $169.6K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 168,534 | 94 | -99.9% | $615.00 | 2025-Q3 |
| UBS Group AG | ADD | 93,612 | 161,900 | +72.9% | $697.8K | 2025-Q2 |
| ROYAL BANK OF CANADA | DOUBLED | 1,459 | 7,429 | +409.2% | $32.0K | 2025-Q2 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 4,319,842 | 6,319,842 | +46.3% | $4.3M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 123,647 | 3,513,188 | +2741.3% | $2.4M | 2024-Q4 |
| D. E. Shaw & Co., Inc. | NEAR_EXIT | 1,047,396 | 229,685 | -78.1% | $155.3K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 228,941 | 161,708 | -29.4% | $109.3K | 2024-Q4 |
11 unique insiders with 29 transactions. Net insider value: -$294.7K ($0.00 bought, $294.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | Greene Barry E | Director | AWARD | 15,508 | — | — |
| May 21, 2026 | Su Zhen | Director | AWARD | 15,508 | — | — |
| May 21, 2026 | Schor Chen | Director | AWARD | 15,508 | — | — |
| May 21, 2026 | Oliger Christy J. | Director | AWARD | 15,508 | — | — |
| May 14, 2026 | Mano Michael | EVP, CLO&Secretary | SELL | 266 | $9.50 | $2.5K |
| May 14, 2026 | Paulson Richard A. | President and CEO | SELL | 2,203 | $9.50 | $20.9K |
| May 14, 2026 | Abate Kristin | Chief Accounting Officer | SELL | 53 | $9.50 | $503.50 |
| May 14, 2026 | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | SELL | 324 | $9.50 | $3.1K |
| May 14, 2026 | Rangwala Reshma | EVP & Chief Medical Officer | SELL | 408 | $9.50 | $3.9K |
| May 14, 2026 | Poulton Stuart | EVP, Chief Development Officer | SELL | 403 | $9.50 | $3.8K |
| May 13, 2026 | Mano Michael | EVP, CLO&Secretary | AWARD | 700 | — | — |
| May 13, 2026 | Paulson Richard A. | President and CEO | AWARD | 4,920 | — | — |
| May 13, 2026 | Abate Kristin | Chief Accounting Officer | AWARD | 121 | — | — |
| May 13, 2026 | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | AWARD | 947 | — | — |
| May 13, 2026 | Rangwala Reshma | EVP & Chief Medical Officer | AWARD | 947 | — | — |
| May 13, 2026 | Poulton Stuart | EVP, Chief Development Officer | AWARD | 896 | — | — |
| Apr 21, 2026 | Rangwala Reshma | EVP & Chief Medical Officer | SELL | 449 | $8.94 | $4.0K |
| Mar 2, 2026 | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | SELL | 4,604 | $9.41 | $43.3K |
| Mar 2, 2026 | Mano Michael | EVP, CLO&Secretary | SELL | 3,526 | $9.41 | $33.2K |
| Mar 2, 2026 | Paulson Richard A. | President and CEO | SELL | 12,361 | $9.41 | $116.3K |
| Mar 2, 2026 | Abate Kristin | Chief Accounting Officer | SELL | 559 | $9.41 | $5.3K |
| Mar 2, 2026 | Rangwala Reshma | EVP & Chief Medical Officer | SELL | 5,066 | $9.41 | $47.7K |
| Feb 5, 2026 | Paulson Richard A. | President and CEO | AWARD | 81,060 | — | — |
| Feb 3, 2026 | Macomber Lori | EVP, CFO & Treasurer | SELL | 1,626 | $6.30 | $10.2K |
| Jan 31, 2026 | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | AWARD | 32,415 | — | — |
| Jan 31, 2026 | Rangwala Reshma | EVP & Chief Medical Officer | AWARD | 32,415 | — | — |
| Jan 31, 2026 | Macomber Lori | EVP, CFO & Treasurer | AWARD | 32,415 | — | — |
| Jan 31, 2026 | Mano Michael | EVP, CLO&Secretary | AWARD | 32,415 | — | — |
| Jan 31, 2026 | Poulton Stuart | EVP, Chief Development Officer | AWARD | 32,415 | — | — |
11 SEC filing reports analyzed. Sentiment: 0 bullish, 5 bearish, 1 mixed, 5 neutral. Avg impact: 4.9/10.
NEUTRAL
CLUSTER
3/10
Six KPTI insiders, including the CEO and other C-suite executives, sold a total of $35K in shares on
May 26, 2026
NEUTRAL
CLUSTER
2/10
Six KPTI insiders, including CEO Richard Paulson, sold shares on May 14 (the same day as Q1 earnings
May 26, 2026
BEARISH
CLUSTER
6/10
Six Karyopharm executives, including the CEO and C-suite, sold a total of $35K in open-market shares
May 15, 2026
NEUTRAL
CLUSTER
3/10
Five Karyopharm insiders, including the CEO and C-suite, sold a total of $31K in open-market sales o
May 15, 2026
BEARISH
CLUSTER
6/10
Karyopharm's CEO, CAO, and EVP/CLO sold a total of $23K in open-market shares on May 14, 2026, the s
May 15, 2026
BEARISH
EFFECT
7/10
Two shelf registrations effective: a $400M universal shelf (including $100M ATM) and an 8.8M-share r
May 15, 2026
MIXED
8-K
6/10
Karyopharm reported Q1 2026 total revenue of $35.1M (up 17% YoY) and a net loss of $22.4M ($1.02 per
May 14, 2026
NEUTRAL
S-3
3/10
Karyopharm filed an S-3 shelf registration for the resale of up to 8,843,036 shares by RA Capital He
May 4, 2026
BEARISH
S-3
7/10
Karyopharm filed a $400M universal shelf registration (including a $100M ATM) representing ~202% of
May 4, 2026
NEUTRAL
CLUSTER
3/10
KPTI insiders sold a combined $164K in open-market transactions over the past week, including CEO Ri
Mar 3, 2026
BEARISH
8-K
8/10
Karyopharm Therapeutics amended its credit agreement and entered into a forbearance agreement with i
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 4 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$13.50 mean target
+48.4% upside
Strong Buy (1.57)
$7.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $9.10 |
| Target Low | $7.00 |
| Target Mean | $13.50 |
| Target Median | $14.50 |
| Target High | $16.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.57) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.39 | $-1.68 | $-1.11 | 65.9% | -22.7% | 0↑ 1↓ | $0.0B | -12.7% | 3 |
| Next Q 2026-09-30 |
$-1.21 | $-1.61 | $-0.81 | 68.2% | -8.0% | 0↑ 1↓ | $0.0B | -23.2% | 3 |
| Current FY 2026-12-31 |
$-4.95 | $-6.03 | $-3.58 | 59.5% | -3.7% | 1↑ 0↓ | $0.1B | -6.1% | 3 |
| Next FY 2027-12-31 |
$-4.89 | $-6.57 | $-3.21 | 1.3% | -12.0% | 0↑ 1↓ | $0.2B | 13.2% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.387 | |
| 7d ago | $-1.387 | |
| 30d ago | $-1.130 | -0.257 |
| 60d ago | $-1.100 | -0.287 |
| 90d ago | $-0.920 | -0.467 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 27, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Mar 30, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Mar 25, 2026 | Baird | MAINTAIN | Outperform | Outperform |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | Rodman & Renshaw | INITIATE | — | Buy |
| Feb 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 5, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Jan 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
Clinical Trial
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Phase Phase 2 — TERMINATED
Jun 3, 2026
Clinical Trial
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Jun 3, 2026
clinical_trial_readout
T-90d Trial Readout: Selinexor (Phase 2)
Trial: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
Sponsor: Karyopharm
May 14, 2026
earnings_calendar
KPTI Q1 2026 Earnings Scheduled — 2026-05-14
Apr 30, 2026
earnings_calendar
KPTI Q1 2026 Earnings Scheduled — 2026-04-30
Apr 20, 2026
short_interest
FTD: KPTI — 60,981 shares ($0.5M) failed to deliver
Settlement: 20260420, Price: $8.61, FTD Value: $525,046.41, KARYOPHARM THERAPEUTICS INC CO
Apr 13, 2026
Clinical Trial
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]
Phase Phase 3 — COMPLETED
Mar 25, 2026
short_interest
FTD: KPTI — 381,337 shares ($2.1M) failed to deliver
Settlement: 20260325, Price: $5.44, FTD Value: $2,074,473.28, KARYOPHARM THERAPEUTICS INC CO
Mar 24, 2026
short_volume
Short Volume: KPTI — 62.2% short (2.3M / 3.8M)
Short: 2,344,223 | Exempt: 131,437 | TRF Vol: 3,770,648 | Short Ratio: 62.2% | Off-exchange volume (dark pool + OTC)
Mar 16, 2026
short_interest
FTD: KPTI — 87,585 shares ($0.7M) failed to deliver
Settlement: 20260316, Price: $7.85, FTD Value: $687,542.25, KARYOPHARM THERAPEUTICS INC CO
Mar 9, 2026
short_interest
FTD: KPTI — 131,193 shares ($1.2M) failed to deliver
Settlement: 20260309, Price: $8.77, FTD Value: $1,150,562.61, KARYOPHARM THERAPEUTICS INC CO